Fuda Cancer Hospital NanoKnife (IRE): Evidence, Risks & Case Fit
NanoKnife is the trade name commonly used for irreversible electroporation (IRE), a non-thermal local-ablation technique that uses short high-voltage electrical pulses. FUDA currently lists IRE in its treatment directory and has a long research and clinical-history footprint around pancreatic and other difficult solid tumors.
Quick answer: FUDA clearly has an active NanoKnife/IRE program, but the strongest reason to consider it is
not that it is “new” or “minimally invasive.” The key question is whether a local ablation adds value for
the patient’s exact cancer, stage, anatomy and prior therapy. For pancreatic cancer, independent evidence remains mixed:
a 2024 expert consensus describes selected use in stage III or inoperable recurrent disease, while a 2025 systematic
review of 38 clinical studies argued against routine IRE use because outcomes and adverse-event burden remain uncertain.
✓ IRE is local treatment, not systemic therapy
✓ FUDA claims separated from independent evidence
✓ Completed trials are not presented as current access
✓ No cure or success-rate guarantee
What Is NanoKnife / Irreversible Electroporation?
Non-thermal electrical ablation
IRE places electrode probes in or around the target and delivers short electrical pulses that create irreversible membrane disruption in cells. Unlike radiofrequency or microwave ablation, the intended effect is not produced by heating the tumor.
Used around difficult structures
FUDA and the wider IRE literature emphasize potential use near major vessels, bile ducts and other structures where thermal ablation can be difficult. That does not make every vessel-adjacent tumor suitable for IRE.
Regulatory wording matters. FUDA’s older IRE page says NanoKnife was “approved by FDA” in 2011.
The official U.S. FDA 510(k) record for K102329 is a substantial-equivalence clearance with an intended use for
surgical ablation of soft tissue. It is not a disease-specific FDA approval for pancreatic, liver,
prostate or another cancer.
What FUDA Currently Says It Does With NanoKnife
FUDA continues to list IRE in its current therapies directory. Its legacy IRE page names pancreas, liver, lung, kidney and prostate among potential solid-organ applications, while 2026 hospital news shows current activity focused heavily on pancreatic and liver ablation under CT and ultrasound guidance.
IRE remains an active FUDA therapy category
FUDA’s 2026 therapies directory still lists Irreversible Electroporation (IRE) alongside cryoablation and other interventional treatments.
WATA training: liver + pancreatic IRE
FUDA reported Niu Lizhi presenting NanoKnife for liver and pancreatic tumors under combined ultrasound and CT guidance at WATA 2026.
Pancreatic IRE + systemic therapy
FUDA reported conference presentations on synchronized IRE with chemotherapy and immunotherapy for pancreatic cancer. These are provider-reported academic activity signals, not independent proof of superiority.
Who Might Be Considered for IRE?
For pancreatic tumors, a 2024 modified-Delphi consensus among IRE experts said pancreatic IRE should be considered
for stage III pancreatic cancer and for inoperable recurrent disease after previous local treatment.
This is an expert consensus on IRE practice, not a universal oncology guideline or a statement that every stage III patient should receive IRE.
Locally advanced disease with a local-control question
IRE may enter discussion when disease is locally advanced, surgery is not feasible and the patient has already undergone appropriate multidisciplinary staging and systemic-treatment planning.
Metastatic or biologically aggressive disease
When cancer is widely metastatic, a local ablation does not treat disease throughout the body. Ask what clinical goal IRE would serve and whether it changes systemic management.
Tumor location and safe electrode placement
The relationship to vessels, ducts, bowel, stomach, nerves and prior surgical anatomy can determine whether IRE is technically feasible or too risky.
Systemic therapy still matters
For pancreatic cancer especially, IRE should be evaluated in the context of modern chemotherapy and multidisciplinary care rather than as a replacement for systemic treatment.
Pancreatic Cancer Evidence: Why the Answer Is Not Simply “Yes” or “No”
Selected-stage use, standardized technique
A modified-Delphi consensus reached agreement on patient selection, procedure settings and follow-up. It supports considering IRE in selected stage III pancreatic cancer and inoperable recurrence, while also acknowledging that major evidence and protocol questions remain.
2,245 patients · substantial adverse-event burden
A 2025 systematic review analyzed 38 clinical IRE studies covering 2,245 pancreatic-cancer patients. Reported median overall survival was 17.2 months, while adverse events occurred in 36% and roughly half were severe. The authors said their analysis argued against routine IRE use in PDAC.
How ParkMega interprets this: IRE is neither “proven useless” nor an established replacement for standard
pancreatic-cancer treatment. It is an indication-sensitive local technique with conflicting evidence. A FUDA recommendation
should therefore be checked against stage, systemic-treatment history, anatomy, treatment goal and alternatives.
FUDA’s Own IRE Research Footprint
| Evidence | What it studied | Status / size | How we use it |
|---|---|---|---|
| NCT02981719 | IRE with gemcitabine vs IRE in locally advanced pancreatic cancer | Completed · 61 actual participants in registry | Historical FUDA research evidence; not a current recruitment route. |
| PMID 30863100 | Prospective cohort of IRE with or without chemotherapy for unresectable pancreatic carcinoma | 54 patients | Supports documented clinical-research experience; major IRE-related complications were reported in 7.4%. |
| NCT02329106 | Percutaneous IRE for unresectable liver cancer near the diaphragmatic dome | Completed / legacy registry program | Shows FUDA historically studied IRE beyond pancreas; does not prove current indication or access. |
| NCT02335827 | IRE for unresectable renal tumors | Completed · estimated 15 participants | Historical renal IRE research; not a current recruiting pathway. |
A completed trial or paper proves that FUDA investigated a technique. It does not establish current international-patient eligibility, current device configuration, present doctor availability or comparative superiority.
Risks and Contraindications: What Needs to Be Checked Before IRE
Cardiac / device / ascites checks matter
The 2024 pancreatic-IRE consensus lists ventricular arrhythmias, implanted stimulation devices, NYHA class IV heart failure and severe ascites as absolute contraindications.
“Minimally invasive” does not mean low-risk
Published pancreatic IRE literature includes pancreatitis, bleeding, thrombosis, fistula, infection, biliary or gastrointestinal complications and procedure-related mortality in some series.
Electrical pulses require procedural planning
Traditional IRE commonly requires anesthesia and coordination around muscle contraction and cardiac synchronization. Any newer local-anesthesia or single-needle approach should be judged on its own device, protocol and validation.
Response assessment is not just “tumor disappeared”
The 2024 consensus recommends contrast-enhanced CT at about one month after pancreatic IRE and then every three months, highlighting the need for structured follow-up rather than anecdotal immediate imaging.
FUDA’s 2026 Single-Needle / Local-Anesthesia NanoKnife Reports
Technology watch — not established evidence. In August–September 2026, FUDA published treatment stories
describing a newer single-needle bipolar IRE approach, including a pancreatic-cancer procedure under local anesthesia.
FUDA presents this as a technical advance. ParkMega treats it as a provider-reported innovation that still
requires independent validation, device/regulatory verification, reproducibility and longer-term outcome data.
If a patient receives a proposal for “single-needle NanoKnife,” ask for the exact device name, regulatory status, whether the approach is conventional IRE or a different pulsed-electric-field platform, who has published clinical data, anesthesia plan, expected complications and why this configuration is preferable for the specific anatomy.
NanoKnife vs Surgery, Thermal Ablation and Systemic Therapy
| Option | Primary role | Key advantage | Key limitation |
|---|---|---|---|
| Surgery | Potential curative local treatment when a tumor is resectable and patient is operable | Removes the tumor and enables full pathology | Not feasible for many locally advanced tumors; larger physiologic burden |
| IRE / NanoKnife | Selected local ablation | Non-thermal; may be useful near some critical structures | Evidence is indication-specific; morbidity can be significant; does not treat systemic disease |
| RFA / Microwave | Thermal local ablation | Established local-ablation tools for selected organs / lesions | Heat-sink and thermal-injury constraints can matter near vessels / ducts |
| Cryoablation | Cold-based local ablation | Ice-ball visualization during treatment | Different organ-specific evidence and complication profile; not interchangeable with IRE |
| Chemotherapy / targeted / immunotherapy | Systemic cancer treatment | Treats disease beyond one local lesion | Systemic toxicity and resistance; choice depends on cancer biology |
Which FUDA Doctors Are Linked to NanoKnife / IRE?
Prof. Niu Lizhi
FUDA repeatedly links Niu Lizhi with complex minimally invasive ablation and IRE, including 2026 presentations on pancreatic and liver NanoKnife. Administrative-title wording varies across FUDA pages, so case routing should focus on his clinical role and actual availability.
Dr. Liu Shupeng
FUDA’s doctor profile lists IRE along with cryoablation, microwave, radiofrequency ablation and brachytherapy. His PubMed record also includes pancreatic IRE research.
See the full Fuda Cancer Hospital Doctors guide for specialty mapping and the difference between a published profile and confirmed appointment availability.
What Records Are Needed for a NanoKnife Case Review?
Core oncology records
- Pathology report and histologic diagnosis
- Current stage and known metastatic sites
- Recent contrast CT and/or MRI
- PET-CT when clinically relevant
- DICOM imaging files, not only screenshots
- Previous surgery, radiation and systemic-treatment history
- Relevant biomarkers / molecular testing
IRE-specific questions
- Exact tumor dimensions and relation to major vessels / ducts
- Why surgery is not feasible or not preferred
- Whether induction chemotherapy has already been given
- Cardiac history, arrhythmias and implanted stimulation devices
- Ascites, performance status and organ function
- What the clinical goal is: local control, symptom relief or another objective
Questions to Ask FUDA Before Accepting a NanoKnife Proposal
Why IRE for this exact case?
Ask what disease feature makes IRE preferable to surgery, radiation, thermal ablation, systemic therapy or observation.
Who will perform it?
Confirm the responsible physician, department, campus and current procedural team—not only a famous doctor shown on the website.
Which IRE system and protocol?
Ask whether conventional multi-electrode NanoKnife or a newer single-needle / bipolar platform is planned, and what clinical evidence supports that configuration.
What are the main patient-specific risks?
Ask about bowel, vascular, ductal, cardiac and anesthesia risks based on the actual scans and comorbidities.
What systemic therapy continues before or after IRE?
For pancreatic and other aggressive cancers, local ablation should be integrated with systemic disease management when appropriate.
What is the written estimate?
Request procedure, anesthesia, imaging, probes/consumables, medicines, room, expected stay, follow-up imaging and likely exclusions.
How Much Does FUDA NanoKnife Cost?
A reliable current NanoKnife quote cannot be inferred from a generic online price. Cost depends on tumor anatomy,
number and type of probes, imaging guidance, anesthesia, inpatient stay, additional procedures, medicines and whether
systemic treatment is delivered around the ablation.
Use the dedicated Fuda Cancer Hospital Cost guide to evaluate the written estimate. A low “procedure price” is not comparable with an all-in hospital estimate unless the same items are included.
How ParkMega Reviews a FUDA NanoKnife Proposal
Start with the scans and stage, not the technology name
Send pathology, stage, DICOM imaging or reports, prior treatment and any FUDA proposal. The useful question is whether IRE is medically relevant, what evidence level applies, what must be verified with FUDA, and whether another China oncology center should be compared before travel.
Related FUDA and China Cancer Guides
Frequently Asked Questions
Direct answers about FUDA NanoKnife / IRE evidence, eligibility, risks, doctors, access and cost.
What is NanoKnife at Fuda Cancer Hospital?
NanoKnife is a commonly used trade name for irreversible electroporation, or IRE. FUDA lists IRE as a non-thermal local-ablation treatment that uses short electrical pulses delivered through probes. It is a local treatment, so it does not treat cancer throughout the body.
Is NanoKnife FDA approved for pancreatic cancer?
No disease-specific FDA approval should be inferred from that wording. The U.S. FDA 510(k) record for the NanoKnife System states an intended use for surgical ablation of soft tissue. A 510(k) substantial-equivalence clearance is not the same as FDA approval of NanoKnife as a pancreatic-cancer treatment.
Does FUDA currently perform NanoKnife / IRE?
FUDA continues to list IRE in its current therapies directory, and 2026 hospital news reports ongoing clinical and academic activity involving NanoKnife for pancreatic and liver tumors. Current device configuration, doctor availability and case acceptance should still be confirmed directly.
Who may be considered for pancreatic IRE?
A 2024 modified-Delphi expert consensus said pancreatic IRE should be considered for selected stage III pancreatic cancer and inoperable recurrent disease after previous local treatment. This is expert consensus, not a universal recommendation for every stage III patient.
What are the main contraindications for pancreatic IRE?
The 2024 expert consensus lists ventricular arrhythmias, implanted stimulation devices, NYHA class IV heart failure and severe ascites as absolute contraindications. Other anatomy, anesthesia and comorbidity factors also need individual review.
Is NanoKnife proven to improve survival in pancreatic cancer?
Evidence is mixed. Some cohort studies report encouraging outcomes, but a 2025 systematic review of 38 clinical IRE studies involving 2,245 patients found substantial adverse-event burden and said its analysis argued against routine IRE use in pancreatic ductal adenocarcinoma. IRE should therefore be treated as indication-specific rather than a proven universal survival-improving treatment.
Did FUDA run clinical trials of IRE?
Yes. FUDA sponsored several registered IRE studies, including NCT02981719 in locally advanced pancreatic cancer and legacy studies in liver and renal tumors. These studies are completed or historical and should not be presented as current recruiting trials.
Which FUDA doctors are associated with NanoKnife?
FUDA repeatedly links Niu Lizhi with complex ablation and IRE, and Liu Shupeng’s profile lists IRE among his minimally invasive oncology techniques. A web profile does not guarantee that a named doctor will personally review or perform treatment for an international patient.
What is FUDA’s new single-needle NanoKnife?
In 2026 FUDA published treatment stories describing a newer single-needle bipolar IRE approach, including pancreatic treatment under local anesthesia. ParkMega treats this as provider-reported technical innovation that still needs independent validation, regulatory/device verification and longer-term clinical outcome evidence.
Is NanoKnife safer than surgery or thermal ablation?
It is different, not automatically safer. IRE is non-thermal and may have technical advantages near some critical structures, but pancreatic IRE literature includes serious complications. Surgery, thermal ablation, cryoablation and IRE have different indications, risks and evidence levels.
What records should I send for a FUDA NanoKnife review?
Send pathology, current stage, recent contrast CT/MRI and DICOM files when available, metastatic sites, previous surgery/radiation/systemic therapy, relevant biomarkers, current medicines, cardiac history and any FUDA treatment proposal.
How much does FUDA NanoKnife cost?
A case-specific quote is more useful than a generic online price. Cost can depend on the IRE system and probes, imaging guidance, anesthesia, inpatient stay, medicines, additional procedures and systemic treatment. Ask for a written itemized estimate after the hospital reviews the medical file.
Sources and Evidence
- FUDA — Therapies directory. Current listing of Irreversible Electroporation (IRE). Official FUDA therapies.
- FUDA — Irreversible Electroporation (IRE). Legacy hospital explanation of mechanism, proposed indications and technical claims. Because the page dates to 2015, promotional/regulatory claims are independently checked. Official IRE page.
- U.S. FDA — NanoKnife System K102329. 510(k) record and intended use for surgical ablation of soft tissue; not a disease-specific pancreatic-cancer approval. FDA 510(k).
- Vos et al., 2024 — PMID 38993594. Modified-Delphi consensus on pancreatic IRE patient selection, contraindications, procedure and follow-up. PubMed.
- Marcellier et al., 2025 — PMID 40879173. Systematic review of electroporation for pancreatic ductal adenocarcinoma; 38 IRE studies / 2,245 patients. PubMed.
- Liu et al., 2019 — PMID 30863100. FUDA-affiliated prospective cohort of IRE with or without chemotherapy for unresectable pancreatic carcinoma. PubMed.
- ClinicalTrials.gov NCT02981719. Completed FUDA-sponsored study of simultaneous gemcitabine and IRE for locally advanced pancreatic cancer. ClinicalTrials.gov.
- ClinicalTrials.gov NCT02329106. FUDA-sponsored legacy IRE study in unresectable liver cancer near the diaphragmatic dome. ClinicalTrials.gov.
- ClinicalTrials.gov NCT02335827. Completed FUDA-sponsored IRE study in unresectable renal tumors. ClinicalTrials.gov.
- FUDA — WATA 2026. Hospital-reported current activity: NanoKnife for liver and pancreatic tumors under CT/ultrasound guidance. FUDA report.
- FUDA — APSCVIR / ISMIO 2026. Hospital-reported activity around pancreatic IRE combined with systemic treatment. FUDA report.
- FUDA — 2026 treatment stories. Provider-published reports of single-needle / local-anesthesia IRE are treated as technology-watch material, not independent efficacy evidence. FUDA stories.
Freshness note: device models, doctor schedules, current case-selection criteria, price and international-patient access can change. Verify the actual proposal directly with FUDA before travel or payment.
Medical note: This page explains evidence and access. It does not diagnose cancer, recommend IRE for a specific patient, replace multidisciplinary oncology advice or guarantee treatment eligibility or outcome.
Check the Case Before Choosing the Technology
Send the pathology, stage, imaging and treatment history. We can structure the FUDA questions around anatomy, evidence level, contraindications, systemic-treatment sequence, doctor / department and a written cost estimate.
✓ No cure claim
✓ No automatic eligibility
✓ Completed trials labeled historical
✓ Standard therapy compared first
Check whether Fuda NanoKnife / IRE fits your case
Start with pathology, stage, imaging and prior treatment. The goal is to test whether IRE is medically relevant, what evidence level applies, and what must be confirmed with Fuda before travel.